Recent news on Vancocin

ViroPharma Incorporated Reports First Quarter 2007 Financial Results  -  May 2, 2007
PR-Inside.com (Pressemitteilung),Net sales of Vancocin(R) were $49.0 million for the first quarter of 2007, which compares to $29.2 million for the first quarter of 2006.

Robert G. Pietrusko Joins ViroPharma as Vice President of Global ...  -  May 1, 2007
PR-Inside.com (Pressemitteilung),ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by

ViroPharma to Release 2007 First Quarter Financial Results on May ...  -  Apr 19, 2007
PR Newswire (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

C. difficile bacteria is a growing problem  -  Apr 14, 2007
Pueblo Chieftain,Doctors usually prescribe metronidazole (Flagyl) and vancomycin (Vancocin). Unfortunately, some patients relapse after treatment and need more therapy.

Aggressive Screening For 'Superbugs' In Children  -  Apr 20, 2007
Medical News Today (press release),Vancomycin (Vancocin) is currently the only FDA-approved drug for MRSA in children, and only one drug, linezolid (Zyvox), is approved in pediatrics for VRE.

Zacks Analyst Blog Highlights: Website Pros and ViroPharma  -  Apr 9, 2007
Business Wire (press release),...that in vitro dissolution testing should not be considered adequate enough to prove bioequivalence for a potential generic oral vancomycin (Vancocin).

ViroPharma: Still Impressive  -  Apr 2, 2007
Seeking Alpha,During the quarter and twelve months ended December 31, 2006, net sales of Vancocin decreased 4.6% and increased 32.4%, respectively,compared to the same

ViroPharma: Still a winner  -  Mar 29, 2007
Blogging Stocks...an explanation was provided: "During the quarter and twelve months ended December 31, 2006, net sales of Vancocin decreased 4.6% and increased 32.4%,

ViroPharma Announces Completion Of Convertible Offering  -  27 Mar 2007
PR Newswire (press release),ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2006 ...  -  Feb 28, 2007
Earthtimes.orgNet sales of Vancocin(R) were $38.5 million for the fourth quarter of 2006 and $166.6 million for the twelve months of 2006. This compares to $40.3 million

Veering ViroPharma  -  Mar 2, 2007
Motley FoolShares whipsawed down 33% last March over fears of generic competition for its lead antibiotic compound, Vancocin. But the stock later rebounded as the

Viropharma Shares Fall on Notes Offering  -  Mar 20, 2007
Forbes,The company's key product on the market is Vancocin, which treats gastrointestinal tract infections. Net product sales totaled $166.6 million in 2006.

ViroPharma earnings drop 75 percent  -  Mar 1, 2007
Chester Daily Local Online,Net product sales for its Vancocin treatment for intestinal bacterial infections, the company’s only product in production, fell 5 percent to $38.5 million,

ViroPharma To Present at the Cowen and Company 27th Annual ...  -  Mar 5, 2007
PR Newswire (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

Viropharma "buy," estimates raised  -  Mar 2, 2007
newratings.com...a Maribavir European partnership in 1H07 and a decision on the Vancocin generic drug applications from the OGD/FDA, the analysts say.

ViroPharma Affirms 2007 Guidance  -  Feb 28, 2007
Forbes,...while the gross margin rate for Vancocin, which treats infections of the gastrointestinal tract, is expected to be more than 90 percent.

ViroPharma 4Q Net Income Falls  -  Feb 28, 2007
Forbes,Net product sales for its Vancocin treatment for intestinal bacterial infections fell 5 percent to $38.5 million, while milestone and license fee revenue

Foolish Forecast: Getting Indigestion with ViroPharma  -  Feb 26, 2007
Motley FoolViroPharma was able to see a large spike in gross margins last quarter, as it switched its supplier of Vancocin from Eli Lilly as to OSG Norwich,

ViroPharma Announces Proposed Offering of $200 Million in ...  -  Mar 19, 2007
PR-Inside.com (Pressemitteilung),ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by

Optimer Pharmaceuticals Advances Difimicin into Phase 3 Clinical Trial  -  Mar 15, 2007
PipelineReview.com (press release),...“The Phase 3 protocol compares Difimicin to Vancocin® (oral vancomycin) with the endpoint being non-inferiority, “ said Howard J. Dreskin, who recently

Optimer Pharmaceuticals Advances Difimicin Into Phase 3 Clinical Trial  -  Mar 14, 2007
PharmaLive.com (press release),..."The Phase 3 protocol compares Difimicin to Vancocin(r) (oral vancomycin) with the endpoint being non-inferiority," said Howard J. Dreskin, who recently

C. diff rate tops 1000 a month  -  Mar 8, 2007
Akron Beacon Journal,In most cases, it is treated with two specific antibiotics: metronidazole (Flagyl) or vancomycin (Vancocin ). If treatment fails, the toxins can cause

No weekend grocery talks  -  Mar 3, 2007
San Diego Union Tribune,The trials will compare the drug to Vancocin, which is the only approved drug for the treatment of CDAD. Isis Pharmaceuticals said the US Patent and

NutraCea Announces Distribution Agreement and ViroPharma ...  -  Mar 1, 2007
Financial News USA (press release),Net sales of Vancocin® were $38.5 million for the fourth quarter of 2006 and $166.6 million for the twelve months of 2006. This compares to $40.3 million

Optimer Pharmaceuticals Regains North American Rights to Difimicin ...  -  Feb 27, 2007
Primenewswire (press release),These trials will compare the safety and efficacy of Difimicin to Vancocin(r) (oral vancomycin), which is currently the only FDA-approved drug for the

ViroPharma to Present at the Susquehanna Financial Group ...  -  Feb 23, 2007
PharmaLive.com (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

ViroPharma to Release 2006 Fourth Quarter and Full Year Financial ...  -  Feb 12, 2007
PR Newswire (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

Zacks Analyst Interview Highlights: Abbott Labs and ViroPharma  -  Jan 30, 2007
Business Wire (press release),The stock has been reacting very well lately, and more people are starting to get over their fears about generic Vancocin, which is their lead product.

Viropharma initiated with "market perform"  -  18 Jan 2007
newratings.comSince Vancocin is Viropharma’s only marketed drug, the company may not be able to remain profitable, while investing into the clinical development of its

ViroPharma sees 2007 net sales for Vancocin of $195 mln-$205 mln  -  Jan 8, 2007
ReutersO: Quote, Profile , Research) said it expects 2007 sales of its antibiotic Vancocin to come in at about $195 million to $205 million.

ViroPharma Sets Vancocin Guidance  -  Jan 8, 2007
Forbes,Biotechnology company ViroPharma Inc. said Monday it expects sales of its antibiotic Vancocin in 2006 to range from $162 million to $170 million,

ViroPharma Provides Financial Outlook for 2007  -  Jan 8, 2007
PR Newswire (press release),2007 Net Product Sales Expected to Grow to $195 to $205 Million; Company to Increase Expenses to Advance Clinical Programs and Support Vancocin Growth

ViroPharma Provides Financial Outlook for 2007  -  Jan 8, 2007
PR Newswire (press release),..."I can confirm that our 2006 net Vancocin(R) sales will be within our guidance range of $162 to $170 million, representing strong growth of 27 percent to 35

ViroPharma's Healthy Sales Guidance  -  Jan 9, 2007
Motley FoolAbsent any potential generic competitors entering the market for its only marketed drug, the antibiotic Vancocin, ViroPharma is expecting another strong

Sneak Preview: No Borrowed Conviction  -  Dec 20, 2006
TheStreet.comIt had recently bought a drug called Vancocin from Eli Lilly (LLY - commentary - Cramer's Take). Vancocin was the only drug on the market that could treat a

ViroPharma to Present at the 25th Annual JP Morgan Healthcare ...  -  Jan 3, 2007
PR Newswire (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

Sneak Preview: No Borrowed Conviction  -  Dec 20, 2006
TheStreet.comIt had recently bought a drug called Vancocin from Eli Lilly (LLY - commentary - Cramer's Take). Vancocin was the only drug on the market that could treat a

Value Visible at ViroPharma  -  Dec 19, 2006
TheStreet.comThe prospects of generic Vancocin, however, may already be priced into ViroPharma's stock, and the upside to investing could be significantly greater than

ViroPharma Chooses Medidata Solutions as Its Standard for Global ...  -  Dec 11, 2006
CNW Telbec (Communiqués de presse),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

ViroPharma to Present at Two Upcoming Healthcare Conferences  09 Nov 2006
ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... -Yahoo! News (press release) Daniel B. Soland Joins ViroPharma as Vice President and Chief ...  Nov 7, 2006
This experience not only will lend itself well to broadening and maximizing the potential of Vancocin, as we approach and begin preparations for the potential ... -Earthtimes.org ViroPharma Incorporated Reports Third Quarter and Nine Months 2006 ...  Nov 2, 2006
Highlights during the third quarter include: Vancocin®: -- Net sales of Vancocin grew to a record $55.1 million; -- Record prescriptions for Vancocin grew ... -Yahoo! News (press release) Nothing's Wrong With ViroPharma  Nov 3, 2006
The potential introduction of generic versions of its lead product, Vancocin, which treats infections of the gastrointestinal tract, is possible sometime next ... -Motley Fool ViroPharma Incorporated Reports Third Quarter and Nine Months 2006 ...  Nov 2, 2006
Net sales of Vancocin were $55.1 million for the third quarter of 2006 and $128.2 million for the first nine months of 2006, as compared to $35.7 million and ... -PharmaLive.com (press release), Zacks Analyst Blog Highlights: Oriental Financial, Smith Micro ...  Nov 6, 2006
The company has one approved product, Vancocin Capsules, for the treatment of antibiotic-associated infection, and two mid-stage candidates for viral infections ... -Business Wire (press release), ViroPharma 3Q Profit Jumps 25 Percent  Nov 2, 2006
© 2006 AP. EXTON, Pa. — ViroPharma Inc. said Thursday third-quarter earnings added 25 percent as sales of its leading antibiotic, Vancocin, rose by half. ... -Houston Chronicle, Market Report -- In Play (VPHM)  Nov 2, 2006
Net sales of Vancocin grew to a record $55.1 mln. Co issues in-line guidance for FY06, sees FY06 revs of $162-170 mln vs. $164.05 mln consensus. ... -MSN Money The 50 Fastest  Oct 27, 2006
...in late 2004 for $116 million. Last year, Vancocin accounted for $125.9 million of ViroPharma's $132.42 million in sales. In the ... -Philadelphia Inquirer, Premarket Movers: Oct. Sales Move Stocks  Nov 2, 2006
Wednesday. Exton, Pa.-based Viropharma reported profit for the September quarter rose 25% as sales of antibiotic Vancocin jumped 55%. ... -MSN Money ViroPharma 3Q Profit Jumps 25 Percent and Celgene to Issue 20M ...  Nov 3, 2006
ViroPharma Inc. (Nasdaq:VPHM) said Thursday third-quarter earnings added 25 percent as sales of its leading antibiotic, Vancocin, rose by half. ... -Financial News USA (press release), ViroPharma to Release 2006 Third Quarter Financial Results on ...  Oct 19, 2006
ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium ... -PharmaLive.com (press release), ViroPharma Announces New Health Initiatives To Combat Clostridium ...  Oct 18, 2006
Other related gastrointestinal disorders -- A Pilot Trial of Oral Vancocin(R) in Primary Sclerosing Cholangitis: Primary sclerosing cholangitis, or PSC ... -Medical News Today (press release), Foro de Shell Security - Seguridad informática  Oct 27, 2006
In patients with severe aplastic anemia (SAA) vancocin stromal cells have normal function, including growth factor vancomycin production. ... -Shell Security, ViroPharma Benefits From Viral Marketing  Aug 25, 2006
However, ViroPharma vaulted to profitability with the acquisition of oral Vancocin from Eli Lilly in November 2004. Oral Vancocin ... -Barron's (subscription)

ViroPharma to Present at the 2006 UBS Global Life Sciences ...  Sep 21, 2006
ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... -PR Newswire

Pharma upgrade  Aug 24, 2006
ViroPharma sells Vancocin, an antibiotic to treat bacterial infections of the lower digestive tract. ViroPharma acquired Vancocin ... -Newark Star Ledger

ViroPharma up on data for hepatitis C drug  Aug 29, 2006
...analyst upgraded his rating, saying sales of the company's only current product, the Vancocin antibiotic, may not be hurt by generic competition as early as ... -Penn Live

Targanta Announces Additions to Management Team  Aug 24, 2006
...from new product planning through post launch of numerous pharmaceutical products, including blockbuster brands such as Keflex(R), Ceclor(R), Vancocin(R), and ... -PR Newswire

The Breast Is Yet to Come  Sep 1, 2006
ViroPharma currently sells one drug, Vancocin, an oral treatment for Clostridium difficile-associated disease, a potentially deadly bacterial infection of the ... -Smartmoney.com

Zacks Analyst Blog Highlights: ViroPharma, Marsh & McLennan and ...  Aug 30, 2006
We remain positive on ViroPharma. We believe the company's citizen's petition to delay a generic Vancocin has an excellent chance to win. ... -Business Wire

ViroPharma Announces Positive Data from Phase 1b Combination Study ...  Aug 28, 2006
ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... -Yahoo! News

Neurocrine Offers Workers Options Exchange and Amylin Completes ...  Aug 28, 2006
...analyst lifted his rating on the stock, saying ViroPharma may get a longer period of exclusivity of its colitis drug Vancocin and pointing to a strong drug ... -Financial News USA

US BioDefense Retains Emergency Preparedness Industry Leader and ...  Aug 25, 2006
...said the company has provided solid scientific arguments against the Office of Generic Drugs's decision to allow a generic version of Vancocin, its antibiotic ... -Financial News USA

Targanta announces additions to Management Team  Aug 25, 2006
...new product planning through post launch of numerous pharmaceutical products, including blockbuster brands such as Keflex®, Ceclor®, Vancocin®, and Evista ... -American Venture Magazine

ViroPharma Announces Presentation of Additional Maribavir Data at ...  -  12 Dec 2006
PharmaLive.com (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

ViroPharma Chooses Medidata Solutions as Its Standard for Global ...  -  Dec 11, 2006
CNW Telbec (Communiqués de presse),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

ViroPharma to Present at Two Additional Healthcare Conferences  -  Nov 21, 2006
PR Newswire (press release),ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by

ViroPharma?s Generic Fight Takes On FDA Rule Change  22 Jul 2006
...has submitted more paperwork in support of its battle against would-be generic competitors to its lead product, Vancocin, an oral capsule form of vancomycin. ... -Therapeutics Daily (subscription)

Viropharma argues to stop copying of Vancocin  Jun 30, 2006
...a supplement to its petition to stop the US Food and Drug Administration from allowing generic copies to be made of its antibiotic Vancocin based solely on ... -Reuters

ViroPharma Submits Scientific Arguments in Supplement to Vancocin ...  Jun 30, 2006
...for Stay of Action with the FDA regarding the bioequivalence requirements for abbreviated new drug applications (ANDAs) that seek to copy Vancocin capsules. ... -International News Service

(PRN) - The Montreal Climate Exchange is established ... [+]  Jul 12, 2006
...(PRN) - ViroPharma to Discuss Scientific Supplement to Petition for Stay of Action Regarding Generic Vancocin on July 13, 2006 ... [+. ... -Bolsamania.com

ViroPharma to Release 2006 Second Quarter Financial Results on ...  Jul 18, 2006
ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... -PR Newswire

Zacks Bull and Bear of the Day Highlights: ViroPharma, Energy ...  Jul 14, 2006
The company has one approved product, Vancocin Capsules, for the treatment of antibiotic-associated infection, and two mid-stage candidates for viral infections ... -Business Wire

Business news in brief  Jul 4, 2006
...to its petition to try to stop the Food and Drug Administration from allowing lower-cost generic copies to be made of its antibiotic Vancocin based solely on ... -Philadelphia Inquirer

ViroPharma Announces Preclinical Data Supporting Utility Of Non ...  Jun 28, 2006
ViroPharma plans to initially focus its efforts on the opportunity to prevent recurrence of CDAD following treatment with Vancocin. ... -Medical News Today

ViroPharma Selected to Join NASDAQ Global Select Market  Jun 26, 2006
ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... -Yahoo! News

FDA Grants Fast Track Status for ViroPharma's Maribavir for ...  Feb 7, 2006
ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium ... - PR Newswire

Small drug company to eliminate long-term debt  Jan 26, 2006
ViroPharma has reduced its debt, and has become profitable largely based on sales of the antibiotic Vancocin, which had third-quarter sales of $35.7 million. ... - philly.com

Trouble in the gut: when antibiotics work too well  Jan 30, 2006
So far, this bacterium remains susceptible to one or both of two oral antibiotics: Flagyl (metronidazole) and Vancocin (vancomycin), which were used to treat ... - Roanoke Times

ViroPharma Broadens Senior Management  Jan 19, 2006
Mr. Milano has been instrumental in building ViroPharma, including leading efforts in raising $630 million in capital and the acquisition of Vancocin(R) from ... - PR Newswire

ViroPharma to Eliminate Debt  Jan 26, 2006
ViroPharma commercializes Vancocin® approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium ... - Yahoo! News

C. diff cases in region grow.  Jan 20, 2006
Authority reported. The growth of the problem can be seen in sales of Vancocin - the key antibiotic used to treat C. diff. In 2005 ... - philly.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional